Last reviewed · How we verify
NCT05729529
Impact of Alpha Lipoic Acid Efficacy in Burning Mouth Syndrome
NA trial testing Lipoid acid gel in Burning Mouth Syndrome in 60 participants. Status unknown.
25 May 2023
Quick facts
| Lead sponsor | University of Catania |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 60 |
| Start date | 20 January 2020 |
| Primary completion | 25 May 2023 |
| Estimated completion | 30 May 2023 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- Lipoid acid gel
- Placebo
Conditions studied
- Burning Mouth Syndrome — all drugs for Burning Mouth Syndrome →
Sponsor
University of Catania
Who can join
Adults 18 to 75, any sex, with Burning Mouth Syndrome. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A double-blind placebo-controlled trial is conducted in order to evaluate the efficacy of alpha lipoic acid (ALA) and determine the statistical significance of the outcome variables. Burning mouth syndrome (BMS) is defined as an oral burning sensation in the absence of clinical signs which could justify the syndrome. Recent studies suggest the existence of neurological factors as a possible cause of the disease.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05729529
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Burning Mouth Syndrome
Currently open trials in the same condition.
- NCT07016555 — Burning Mouth Syndrome: Symptoms and Management · EARLY_PHASE1 · recruiting
- NCT07381361 — Photobiomodulation Therapy vs. Alpha-Lipoic Acid in Burning Mouth Syndrome Treatment · NA · active not recruiting
- NCT06040190 — Effect of Treatments on Pain and Quality of Life in Individual With Burning Mouth Syndrome · Phase 4 · recruiting
- NCT05819697 — Reducing Patient Memory Recall in the Burning Mouth Patient Population · recruiting
Other University of Catania trials
Trials by the same sponsor.
- NCT07455643 — Closed-loop Response to Unannounced Mixed and Carbohydrates-rich Breakfasts · NA · completed
- NCT06831487 — Analysis of Line-Field Confocal Optical Coherence Tomography (LC-OCT) in Characterization of Gingival Systemic Health, G · NA · enrolling by invitation
- NCT06725095 — Effects of Enamel Matrix Derivative in the Treatment of Peri-implant Mucositis · NA · enrolling by invitation
- NCT06020937 — Olfactory and Trigeminal Functions in Patients With Multiple Sclerosis: Case-control Study · not yet recruiting
- NCT07300657 — Impact of an AI-Based Chatbot on Implant Patient Management: RCT · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05729529 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Catania
- Last refreshed: 15 February 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05729529.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing